Progress and prospects on vaccine development against monkeypox infection

Saadh, Mohamed J.; Ghadimkhani, Tahmineh; Soltani, Narges; Abbassioun, Arian; Daniel Cosme Pecho, Renzon; taha, Ali; Jwad Kazem, Tareq; Yasamineh, Saman; Gholizadeh, Omid

doi:10.1016/j.micpath.2023.106156

Cited by 26 publications

(7 citation statements)

References 174 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…First-generation vaccines like Dryvax and second-generation vaccines such as ACAM2000, which are live replicating vaccinia virus vaccines, can cause severe infections such as progressive vaccinia. 260 The emergence of third-generation vaccines provides an alternative for this specific population. One example is Imvamune (also known as JYNNEOS) a non-replicating vaccinia vaccine that has been tested safe for HIV-infected patients.…”

Section: Prospect and Challengesmentioning

confidence: 99%

Mpox (formerly monkeypox): pathogenesis, prevention and treatment

Lu,

Xing,

Wang

et al. 2023

Sig Transduct Target Ther

View full text Add to dashboard Cite

In 2022, a global outbreak of Mpox (formerly monkeypox) occurred in various countries across Europe and America and rapidly spread to more than 100 countries and regions. The World Health Organization declared the outbreak to be a public health emergency of international concern due to the rapid spread of the Mpox virus. Consequently, nations intensified their efforts to explore treatment strategies aimed at combating the infection and its dissemination. Nevertheless, the available therapeutic options for Mpox virus infection remain limited. So far, only a few numbers of antiviral compounds have been approved by regulatory authorities. Given the high mutability of the Mpox virus, certain mutant strains have shown resistance to existing pharmaceutical interventions. This highlights the urgent need to develop novel antiviral drugs that can combat both drug resistance and the potential threat of bioterrorism. Currently, there is a lack of comprehensive literature on the pathophysiology and treatment of Mpox. To address this issue, we conducted a review covering the physiological and pathological processes of Mpox infection, summarizing the latest progress of anti-Mpox drugs. Our analysis encompasses approved drugs currently employed in clinical settings, as well as newly identified small-molecule compounds and antibody drugs displaying potential antiviral efficacy against Mpox. Furthermore, we have gained valuable insights from the process of Mpox drug development, including strategies for repurposing drugs, the discovery of drug targets driven by artificial intelligence, and preclinical drug development. The purpose of this review is to provide readers with a comprehensive overview of the current knowledge on Mpox.

show abstract

Section: Prospect and Challengesmentioning

confidence: 99%

Mpox (formerly monkeypox): pathogenesis, prevention and treatment

Lu,

Xing,

Wang

et al. 2023

Sig Transduct Target Ther

View full text Add to dashboard Cite

show abstract

“…Drug delivery methods based on nanomaterials are attractive options in the search for therapeutic advantages because of their distinctive properties. Researchers should also examine how the most prevalent viruses, such as the flu, HIV, SARS-CoV-2, monkeypox, and HPVs, are being treated and prevented using the latest advances in nanomedicine [ 4 , 17 , 68 , 69 ]. Bacterial entry into mammalian host cells involves various mechanisms, such as clathrin-mediated endocytosis, caveolin-mediated endocytosis, and membrane fusion.…”

Section: Bacteria and Bacterial Derivatives As Drug Delivery Systems ...mentioning

confidence: 99%

“…The current pandemic outbreak of the new coronavirus is a vivid illustration of the devastating effects on the health and economic development of millions of people throughout the globe [ 1 – 3 ]. Measles, rubella, chickenpox/shingles, SARS-CoV, MERS-CoV, SARS-CoV-2, human immunodeficiency virus)HIV(, chikungunya virus, Ebola virus (EV), hepatitis, influenza, herpes simplex, and Zika virus all showed up in the twenty-first century without any effective antiviral treatments [ 4 – 9 ]. To combat these problems, nanotechnology-based drug delivery is on the rise as a means of boosting therapeutic efficacy via modifying the physicochemical features of antiviral medications [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

The potential use of bacteria and bacterial derivatives as drug delivery systems for viral infection

Faghihkhorasani,

Ahmed,

Mashool

et al. 2023

Virol J

Self Cite

View full text Add to dashboard Cite

Viral infections in humans are responsible for fatalities worldwide and contribute to the incidence of various human ailments. Controllable targeted medicine delivery against many illnesses, including viral infection, may be significantly aided by using bacteria and bacteria-derived products. They may accumulate in diseased tissues despite physical obstacles, where they can launch antiviral immunity. The ability to genetically and chemically modify them means that vaccinations against viral infections may be manufactured and delivered to affected tissues more safely and effectively. The objective of this study is to provide an overview of the latest advancements in the field of utilizing bacteria and bacterial derivatives as carriers for administering medication to treat viral diseases such as SARS-CoV-2, hepatitis B virus, hepatitis C virus, human immunodeficiency virus, human papillomavirus, influenza, and Ebola virus. Graphical Abstract

show abstract

“…Emerging evidence suggests vaccines are an effective adjunct to other public health interventions in the context of the Mpox outbreak response [5] , [11] , [12] , [13] . Judicious use of vaccines can protect vulnerable groups at risk of severe Mpox disease and minimize zoonotic transmission of Mpox virus.…”

Section: Introductionmentioning

confidence: 99%

Mpox knowledge and vaccination hesitancy among healthcare workers in Beijing, China: A cross-sectional survey

Yang,

Zhang,

Han

et al. 2024

Vaccine: X

View full text Add to dashboard Cite

Progress and prospects on vaccine development against monkeypox infection

Cited by 26 publications

References 174 publications

Mpox (formerly monkeypox): pathogenesis, prevention and treatment

Mpox (formerly monkeypox): pathogenesis, prevention and treatment

The potential use of bacteria and bacterial derivatives as drug delivery systems for viral infection

Mpox knowledge and vaccination hesitancy among healthcare workers in Beijing, China: A cross-sectional survey

Contact Info

Product

Resources

About